Levosimendan improves cardiopulmonary resuscitation and survival by K(ATP) channel activation.

摘要

Global myocardial ischemia during cardiac arrest accounts for post-resuscitation myocardial dysfunction. The new myofilament Ca~(++) sensitizer, levosimendan, is of potential benefit in this setting, for it improves myocardial contractility without increasing myocardial oxygen consumption. Experimentallylevosimendan produces dose-dependent increases in contractility without adverse effects on diastolic function.